Prospective study of exercise intervention in prostate cancer patients on androgen deprivation therapy

Journal of Medical Imaging and Radiation Oncology

Volumn 58, Issue 3, 2014, Pages 369-376

  Beydoun, Nadine ^a   Bucci, Joseph A ^a   Chin, Yaw S ^a   Spry, Nigel ^b,c,d   Newton, Robert ^d   Galvão, Daniel A ^d  

^a ST GEORGE HOSPITAL   (Australia)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d EDITH COWAN UNIVERSITY   (Australia)

Author keywords

androgen deprivation; cardiovascular disease; physical exercise; prostate cancer

Indexed keywords

LEUPRORELIN; ANTIANDROGEN;

AEROBIC EXERCISE; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY COMPOSITION; CANCER RECURRENCE; CANCER THERAPY; CARDIOPULMONARY FUNCTION; CONTROLLED STUDY; FITNESS; HUMAN; KINESIOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MUSCLE STRENGTH; PATIENT PREFERENCE; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; QUALITY OF LIFE; RESISTANCE TRAINING; TELEPHONE INTERVIEW; TREATMENT WITHDRAWAL; WELLBEING; AUSTRALIA; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COMORBIDITY; METABOLIC DISEASES; MULTICENTER STUDY; PREVALENCE; PROSTATIC NEOPLASMS; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; AUSTRALIA; CARDIOVASCULAR DISEASES; CAUSALITY; COMBINED MODALITY THERAPY; COMORBIDITY; EXERCISE THERAPY; HUMANS; LEUPROLIDE; MALE; METABOLIC DISEASES; PREVALENCE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME;

EID: 84901826340     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/1754-9485.12115     Document Type: Article

References (28)

1. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-1252. (Pubitemid 32727802)
2. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-106.
3. Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU,. Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure. Prostate Cancer Prostatic Dis 2009; 12: 233-240.
4. Keating NL, O'Malley AJ, Smith MR,. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006; 24: 4448-4456. (Pubitemid 46630983)
5. Tsai HK, D'Amico AV, Sadetsky N, et al. Androgen deprivation therapy for localised prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007; 99: 1516-1524. (Pubitemid 351767235)
6. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007; 25: 2420-2425. (Pubitemid 46999213)
7. Smith MR, Lee H, Nathan DM,. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006; 91: 1305-1308.
8. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C,. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003; 104: 195-201. (Pubitemid 36238052)
9. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002; 87: 599-603. (Pubitemid 34158224)
10. Galvao DA, Spry NA, Taaffe DR, et al. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 2008; 102: 44-47. (Pubitemid 351799442)
11. Smith JC, Bennett S, Evans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001; 86: 4261-4267. (Pubitemid 32848544)
12. Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S,. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 2006; 18: 494-498. (Pubitemid 44330303)
13. Smith MR, Lee H, McGovern F, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008; 112: 2188-2194. (Pubitemid 351628628)
14. Punnen S, Cooperberg MR, Sadetsky N, Carroll PR,. Androgen deprivation therapy and cardiovascular risk. J Clin Oncol 2011; 29: 3510-3516.
15. Trivedi DP, Khaw KT,. Dehydroepiandrosterone sulfate and mortality in elderly men and women. J Clin Endocrinol Metab 2001; 86: 4171-4177. (Pubitemid 32848531)
16. Bong GW, Clarke HS Jr, Hancock WC, Keane TE,. Serum testosterone recovery after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Urology 2008; 71: 1177-1180.
17. Kaku H, Saika T, Tsushima T, et al. Time course of serum testosterone and luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate 2006; 66: 439-444. (Pubitemid 43346954)
18. Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU,. Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomised controlled trial. J Clin Oncol 2010; 28: 340-347.
19. Helmrich SP, Ragland DR, Paffenbarger RS Jr,. Prevention of non-insulin-dependent diabetes mellitus with physical activity. Med Sci Sports Exerc 1994; 26: 824-830. (Pubitemid 24200619)
20. Wannamethee SG, Shaper AG, Walker M,. Changes in physical activity, mortality, and incidence of coronary heart disease in older men. Lancet 1998; 351: 1603-1608. (Pubitemid 28252175)
21. Lee IM, Sesso HD, Paffenbarger RS Jr,. Physical activity and coronary heart disease risk in men: does the duration of exercise episodes predict risk? Circulation 2000; 102: 981-986. (Pubitemid 30656006)
22. Lee IM, Paffenbarger RS Jr,. Associations of light, moderate, and vigorous intensity physical activity with longevity. The Harvard Alumni Health Study. Am J Epidemiol 2000; 151: 293-299. (Pubitemid 30463634)
23. Newton RU, Galvao DA,. Exercise in prevention and management of cancer. Curr Treat Options Oncol 2008; 9: 135-146.
24. Nelson ME, Rejeski WJ, Blair SN, et al. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. Med Sci Sports Exerc 2007; 39: 1435-1445. (Pubitemid 47344027)
25. Newman AB, Simonstick EM, Naydeck BL, et al. Association of long-distance corridor walk performance with mortality, cardiovascular disease, mobility limitation, and disability. JAMA 2006; 295: 2018-2026. (Pubitemid 44794004)
26. Taaffe DR,. Sarcopenia. Exercise as a treatment strategy. Aust Fam Physician 2006; 35: 130-134.
27. Ruiz JR, Sui X, Lobelo F, et al. Association between muscular strength and mortality in men: prospective cohort study. BMJ 2008; 337: a439.
28. Segal RJ, Reid RD, Courneya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003; 21: 1653-1659. (Pubitemid 46638574)